Neurocrine BiosciencesNBIX

• Phase 2경도·중등도 알츠하이머병 대상 NBI-1117567 임상시작 전Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase Inhibitor
  65%
• Phase ?선천성 부신과형성증 청소년 의료전환 연구시작 전Development of Healthcare Transition for Patients With Congenital Adrenal Hyperplasia
  59%
• Phase 3선천성 부신과다형성증 치료제 크리네세르폰트 글로벌 3상진행 중Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
  38%
• Phase ?발베나진 성인 지연성 운동장애 치료 임상모집 중A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
  73%
• Phase 2Crinecerfont 4세 미만 부신과형성증 임상시작 전Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
  53%
• Phase 3발베나진 헌팅턴병 무도증 치료 장기 안전성 임상진행 중Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada
  31%
• Phase 2크리네세르폰트 2세 미만 선천성 부신과형성증 임상모집 중Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
  53%
• Phase 3발베나진 뇌성마비 이상운동증 치료 임상진행 중Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
  57%
• Phase 3크리네세르폰 소아 선천성 부신과형성증 글로벌 3상 임상진행 중Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
  38%
• Phase 3발베나진 헌팅턴병 무도증 장기 투약 임상진행 중Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
  31%
• Phase 3주요 우울장애 보조치료제 NBI-1065845 유효성 임상모집 중Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  82%
• Phase 3주요우울장애 보조요법 NBI-1065845 유효성 임상모집 중NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  82%

성공 확률은 BERA의 AI 모델(임상 설계·약물 구조·과거 사례 기반)이 계산한 값이에요. 실제 결과와 다를 수 있어요.